Five things for pharma marketers to know: Monday, January 29, 2018

Share this content:

1. Outcome Health secured a deal with investors, including units of Goldman Sachs and Google, to settle allegations that it shared misleading information about the company's performance. As part of the agreement, Outcome CEO Rishi Shah and president Shradha Agarwal have removed themselves from day-to-day management of the company. (Chicago Tribune)

2. According to a report issued by the Department of Health and Human Services, the Food and Drug Administration approved a record number of generic medicines during the first year of the Trump presidency. The FDA approved 1,027 generic drugs in 2017, up from a then-record-setting 800 in 2016. (U.S. Department of Health and Human Services)

3. Sanofi acquired Belgian biotech company Ablynx, the maker of a drug that has shown promise in the treatment of a rare clotting disorder, acquired thrombotic thrombocytopenic purpura, for $4.8 billion. Ablynx previously declined two acquisition bids from Novo Nordisk. (Endpoints News)

4. The Food and Drug Administration has granted breakthrough therapy designation to balovaptan, Roche said on Monday. The drug is designed to improve communication and social interaction for patients suffering from autism spectrum disorder. (Reuters)

5. The Food and Drug Administration has shut down a nicotine addiction study after the deaths of four squirrel monkeys used as research subjects. The agency will establish a council to oversee all subsequent animal studies. (The New York Times)
Share this content:
Scroll down to see the next article